According to a recent study, antimicrobial resistance (AMR) is prevalent throughout Europe and 670,000 people in the European Union/European Economic Area (EU/EEA) get afflicted with antibiotic-resistant bacteria each year. According to the study around 33,000 people died as a direct consequence of antibiotic resistant bacteria infections.
- MAJOR PEER REVIEWED STUDY: Moderna Vaccine Increases Myocarditis Risk By 44 Times In Young Adults
- MUST READ: High Level International Bankers Simulate The Collapse Of Global Financial System
- BIG STORY: Wuhan Lab Isolated Monkeypox Strain In 2020
- EXPLOSIVE: Ukraine Biolabs Used Fever Carrying Mosquitoes To Spark Dengue Pandemic In Cuba
As per a research (read below) by the European Center for Disease Prevention and Control (ECDC) and the World Health Organization (WHO) Regional Office for Europe, almost 33,000 individuals perished as a direct result of these diseases.
The findings were founded on antimicrobial resistance information from invasive isolates submitted to the Central Asian and European Surveillance of Antimicrobial Resistance (CAESAR) and European Antimicrobial Resistance Surveillance Network (EARS-Net) networks in 2021. (data referring to 2020).
EARS-Net got statistics from 29 countries, comprising all from the EU and two from the EEA (Iceland and Norway), whereas CAESAR acquired information from 12 countries plus Kosovo.
This year, the European Region’s AMR monitoring reporting is 100 percent aligned, thanks to all of the work that started in 2012. Similar regional cooperative surveillance activities (such as tuberculosis and HIV) have led to multiple such reports with ECDC.
Subscribe to GreatGameIndia
Between 2016 and 2020, carbapenem tolerance in E. coli and K. pneumoniae, as well as vancomycin resistance in E. faecium, grew dramatically in the areas. Large proportions of carbapenem-resistant Acinetobacter species and Pseudomonas aeruginosa in K. pneumoniae, as well as carbapenem-resistant Acinetobacter species and Pseudomonas aeruginosa in numerous European countries, have also caused alarm.
ECDC’s director, Andrea Ammon, said:
Everyone – including policy-makers, health professionals, patients and governmental and nongovernmental organizations – has a role to play in addressing the public health threat of AMR.
Following the adoption of the European Strategic Action Plan on Antibiotic Resistance in 2011 and the publication of the Global Action Plan on Antimicrobial Resistance in 2015, most WHO European Region member states have boosted their efforts to tackle AMR.
Only 25 (50%) of the region’s 50 countries/areas declared having developed an AMR national action plan in 2016. (NAP). According to the most recent round of global monitoring, 43 (86%) of the region’s 50 countries/areas replied.
Twenty percent of countries/areas in the WHO European Region reported experiencing no monitoring capability for producing AMR surveillance data or merely gathering AMR data at the local level without a defined strategy.
The research also underlined the impending issue of ensuring that NAPs are fully implemented and adequately funded.
Read the study below: